Romatoid Artritli Hastalarda Soluble Cd30 Düzeyleri

Objective & Hypothesis:Objective: We aimed to determine serum soluble CD30 (sCD30) levels in patients with rheumatoid arthritis (RA) and to analyze their clinical significance in these patients.Materials and Methods: The study group consisted of 49 patients who fulfilled the 1987 American College of Rheumatology diagnostic criteria for RA, and 20 age- and gender-matched healthy controls.

📊

Key Findings & Data:Morning stiffness (minutes), pain (visual analog scale, 0-100 mm VAS), fatigue (5-point scale), patient's and physician's general health assessment (0-100 mm VAS), number of tender and swollen joints (total 28 joints), disease activity (DAS28 score), and physical function capacity (disability) (Turkish version of the health assessment questionnaire, HAQ) were assessed.

💡

Conclusion & Impact:Therefore, we suggest the need for further studies to investigate its clinical importance.

🔬Design:Survey & Empirical Study

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Objective: We aimed to determine serum soluble CD30 (sCD30) levels in patients with rheumatoid arthritis (RA) and to analyze their clinical significance in these patients.Materials and Methods: The study group consisted of 49 patients who fulfilled the 1987 American College of Rheumatology diagnostic criteria for RA, and 20 age- and gender-matched healthy controls. Morning stiffness (minutes), pain (visual analog scale, 0-100 mm VAS), fatigue (5-point scale), patient's and physician's general health assessment (0-100 mm VAS), number of tender and swollen joints (total 28 joints), disease activity (DAS28 score), and physical function capacity (disability) (Turkish version of the health assessment questionnaire, HAQ) were assessed. Presence of extraarticular manifestations was recorded. Radiographic assessment of hands and feet was evaluated according to the modified Sharp method. Routine laboratory tests, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor, immunoglobulins, and complements levels were determined by nephelometry. Serum sCD30 levels of the patients with RA and healthy controls were measured by ELISA.Results: The mean age was 51.1±13.1 years. The mean disease duration was 7.7±5.1 years. The median DAS28 score was 4.3 (2.3-6.8) and the median HAQ score 1.1 . The serum levels of sCD30 were significantly increased in RA patients (25.1±18.3 IU/ml) compared to healthy controls (17.2±8.1 IU/ml) (p=0.004). The mean serum level of sCD30 was not different between the low active and moderate/high active patient groups. There was a correlation between sCD30 level and extraarticular involvement (p=0.009, r=0.37) and physician's general health assessment (p=0.008, r=0.38). Conclusion: The present data suggest a possible involvement of CD30+ T cells in the immune processes of RA. Serum sCD30 levels might be a helpful tool for the evaluation of Th2 activity in RA. However, the relationship between sCD30 and clinical disease activity remains uncertain. Therefore, we suggest the need for further studies to investigate its clinical importance.

Özet

Amaç: Romatoid artritli (RA) hastalarda serum soluble CD30 (sCD30) düzeylerini araştırmak ve klinik önemini analiz etmektir. Yöntem ve Gereçler: 1987 ACR RA tanı kriterlerini karşılayan 49 hasta ile yaş ve cinsiyet açısından benzer olan 20 sağlıklı kontrol grubu üzerinde bu çalışma yapılmıştır. Sabah tutukluğu (dakika), ağrı şiddeti (görsel analog skala, 0-100 mm), yorgunluk (5-noktalı skala), hastanın ve doktorun genel sağlık değerlendirmesi (görsel analog skala, 0-100 mm), şiş ve hassas eklem sayısı (28 eklem), hastalık aktivitesi (DAS28 skoru), özürlülük (Sağlık Değerlendirme Anketi, Türkçe versiyonu) değerlendirildi. Eklem dışı tutulumlar kaydedildi. Radyolojik değerlendirmede eller ve ayaklar modifiye Sharp metoduyla değerlendirildi. Rutin laboratuvar testlerin yanında ESR, CRP, RF, immunoglobulinler ve kompleman düzeyleri nefelometre ile, serum sCD30 düzeyleri ELISA yöntemiyle ölçüldü.Bulgular: Hastaların ortalama yaşı 51.1±13.1 yıldı. Ortalama hastalık süresi 7.7±5.1 yıldı. DAS28 skoru median değeri 4.3 (2.3-6.8) ve HAQ skoru 1.1 olarak bulundu. Romatoid artritli hastalarda serum sCD30 düzeyi (25.1±18.3 IU/ml) kontrollerden (17.2±8.1 IU/ml) anlamlı derecede yüksek bulundu (p=0.004). sCD30 düzeyleri inaktif/düşük aktiviteli hastalık grubu ile orta/yüksek derecede aktif hastalık grubunda farklılık göstermedi (p=0.254). SCD30 düzeyi eklem dışı tutulumla (p=0.009, r=0.37) ve doktorun hastayı genel değerlendirimiyle (p=0.008, r= 0.38) korelasyon gösterdi. Sonuç: Romatoid artritin immün patogenezinde CD30 pozitif T hücrelerinin etkilenmesini destekler, serum CD30 düzeyi romatoid artritli hastalarda Th 2 aktivitesi için yararlı bir gösterge olabilir. Ancak serum sCD30 düzeyinin klinik hastalık aktivite parametreleri ile ilişkisinin varlığı kesin olarak gösterilememiştir. sCD30'un hastalık aktivitesi ve sonuç parametreleriyle ilişkisini araştırmak için geniş ve homojen gruplarda yapılacak çalışmalara ihtiyaç vardır.

🔖

Cite This Article

TUR, B. S., ATAMAN, Ş., SÜLDÜR, N., DÜZGÜN, N., ATAY, M. B. (2009). Romatoid Artritli Hastalarda Soluble Cd30 Düzeyleri. Turkish Journal of Rheumatology(.)Archives of Rheumatology, Cilt: 24 - Sayı: 3, 131–135. https://ajindex.com/articles/345389

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (9)

Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992; 35: 729-35. Tsokos GC. B cells, be gone-B-cell depletion in the treatment of rheumatoid arthritis. N Engl J Med 2004; 350: 2546-8.
Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989; 46: 111-47. Verhoef CM, van Roon JAG, Lafeber FPJG, Bijlsma JWJ. T1/T2 cell balance in rheumatoid arthritis. Clin Applied Immunol Rev 2001; 1: 153-61. Miltenburg AM, van Laar JM, de Kuiper R, Daha MR, Breedveld FC. T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. Scand J Immunol 1992; 35: 603-10.
Schulze-Koops H, Kalden JR. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2001; 15: 677-91. Dolhain RJ, van der Heiden AN, ter Haar NT, Breedveld FC, Miltenburg AM. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1961-9.
Del Prete GF, De Carli M, Almerigogna F, Daniel CK, D'Elios MM, Zancuoghi G, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cell cytokines. FASEB J 1995; 9: 81-6.
Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, Diamanthstein T. Ki-1 (CD30 antigen is released by Ki-1- positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 1989; 19: 157-62.
Gerli R, Bistoni O, Lunardi C, Giacomelli R, Tomassini C, Biagini P, et al. Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy. Rheumatology (Oxford) 1999; 38: 1282-4.
Gerli R, Pitzalis C, Bistoni O, Falini B, Costantini V, Russano A, et al. CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol 2000; 164: 4399- 407. Spinozzi F, Agea E, Bistoni O, Forenza N, Monaco A, Falini B, et al. Local expansion of allergen-specific CD30+Th2-type gamma delta T cells in bronchial asthma. Mol Med 1995; 1: 821-6.
Leonard C, Tormey V, Faul J, Burke CM, Poulter LW. Allergen- induced CD30 expression on T cells of atopic asthmatics. Clin Exp Allergy. 1997; 27: 780-6.
Ruggeri RM, Barresi G, Sciacchitano S, Trimarchi F, Benvenga S, Trovato M